Supernus Pharmaceuticals (NASDAQ:SUPN) Sets New 1-Year High After Strong Earnings

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)’s stock price reached a new 52-week high during mid-day trading on Tuesday after the company announced better than expected quarterly earnings. The stock traded as high as $39.37 and last traded at $36.31, with a volume of 52892 shares traded. The stock had previously closed at $34.70.

The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.25. The firm had revenue of $175.70 million during the quarter, compared to analysts’ expectations of $157.35 million. Supernus Pharmaceuticals had a return on equity of 0.56% and a net margin of 0.83%. The company’s revenue for the quarter was up 14.2% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.29) EPS.

Analyst Ratings Changes

Several equities analysts recently issued reports on SUPN shares. Piper Sandler restated a “neutral” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. StockNews.com upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Finally, Cowen reiterated a “buy” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Armistice Capital LLC increased its stake in shares of Supernus Pharmaceuticals by 47.6% during the second quarter. Armistice Capital LLC now owns 5,272,000 shares of the specialty pharmaceutical company’s stock valued at $141,026,000 after buying an additional 1,700,000 shares during the period. Pacer Advisors Inc. boosted its holdings in Supernus Pharmaceuticals by 100,186.3% in the second quarter. Pacer Advisors Inc. now owns 1,349,854 shares of the specialty pharmaceutical company’s stock valued at $36,109,000 after acquiring an additional 1,348,508 shares in the last quarter. American Century Companies Inc. increased its position in Supernus Pharmaceuticals by 369.1% during the 2nd quarter. American Century Companies Inc. now owns 501,658 shares of the specialty pharmaceutical company’s stock valued at $13,419,000 after purchasing an additional 394,728 shares during the period. Renaissance Technologies LLC raised its holdings in Supernus Pharmaceuticals by 26.4% in the 2nd quarter. Renaissance Technologies LLC now owns 1,685,122 shares of the specialty pharmaceutical company’s stock worth $45,077,000 after purchasing an additional 351,900 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Supernus Pharmaceuticals by 12.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,866,887 shares of the specialty pharmaceutical company’s stock worth $76,690,000 after purchasing an additional 309,966 shares during the period.

Supernus Pharmaceuticals Trading Up 0.1 %

The stock has a market cap of $1.91 billion, a P/E ratio of 386.00 and a beta of 0.86. The business’s 50 day moving average price is $33.02 and its two-hundred day moving average price is $30.50.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.